Share on StockTwits

Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its quarterly earnings data on Tuesday. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.20) by $0.16, AnalystRatings.Net reports. The company had revenue of $11.80 million for the quarter, compared to the consensus estimate of $11.39 million. The company’s quarterly revenue was up 15.7% on a year-over-year basis.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down 4.96% on Tuesday, hitting $16.11. 52,267 shares of the company’s stock traded hands. Oxford Immunotec Global PLC has a 52 week low of $13.58 and a 52 week high of $25.38. The stock’s 50-day moving average is $16.94 and its 200-day moving average is $19.29. The company’s market cap is $282.9 million.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company. The Company’s T-SPOT technology platform allows the Company to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.